The Outputs
To keep the scorecard focused on prospects for future innovation in biotechnology, it avoids hard measures—but they, too, tell a story. For example, measurements of the efficiencies of public biotechnology companies (below) show that the U.S. is far ahead in the market capitalization per company, but Hong Kong and Ireland lead in the revenue generated per company.
SOURCES: Company disclosures and Huggett, B., Hodgson, J., Lähteenmäki, R. 2009. Public biotech 2008—the numbers. Nature Biotechnology 27:710–721.
-
2: Intensity
Measuring a country's biotech "blood pressure" demands multiple approaches -
3: Enterprise Support
Biotechnology thrives only when a country maintains a broad collection of business resources
Worldview Scorecard
| Honduras | Saudi Arabia |
| Hungary | Switzerland |
| Ireland | Uganda |
| Italy | U.S. |
| Japan | Vietnam |
Country Spotlights
-
Brighter Days Ahead
A variety of tools—from emerging-market opportunities to mergers and acquisitions—help companies grow in a recovering market -
Harmonizing Harmonization
A better map for the global regulatory landscape
Perspectives
Advertisement
-
The Elements of Service
A Chinese CEO develops end-to-end contract research and manufacturing capabilities -
Three Biotech Game Changers
Three pioneers describe the building of biotech in India, Brazil and China.
Profiles